Information from Industry

JCP
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
Information from Industry

September 27, 2024

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
JCP
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Information from Industry

June 30, 2020

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe